These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 29417798)
1. Neglected skin carcinomas and Vismodegib: our experience. Russo F; Mancini V; Taddeucci P; Cirocco A; Cusano F; Pellegrino M; Sirna R G Ital Dermatol Venereol; 2019 Oct; 154(5):597-599. PubMed ID: 29417798 [No Abstract] [Full Text] [Related]
2. Local Experience with Vismodegib. Pasquali P Actas Dermosifiliogr (Engl Ed); 2018 Nov; 109(9):765-766. PubMed ID: 30077392 [No Abstract] [Full Text] [Related]
3. Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin. Gathings RM; Orscheln CS; Huang WW J Am Acad Dermatol; 2014 Apr; 70(4):e88-e89. PubMed ID: 24629372 [No Abstract] [Full Text] [Related]
4. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. Aasi S; Silkiss R; Tang JY; Wysong A; Liu A; Epstein E; Oro AE; Chang AL JAMA Dermatol; 2013 Feb; 149(2):242-3. PubMed ID: 23426496 [No Abstract] [Full Text] [Related]
5. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma. Orouji A; Goerdt S; Utikal J; Leverkus M Br J Dermatol; 2014 Aug; 171(2):431-3. PubMed ID: 24446722 [No Abstract] [Full Text] [Related]
6. Vismodegib in basal cell carcinoma. Amaria RN; Bowles DW; Lewis KD; Jimeno A Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657 [TBL] [Abstract][Full Text] [Related]
7. Four-year experience with vismodegib hedgehog inhibitor therapy. Simone PD; Schwarz JM; Strasswimmer JM J Am Acad Dermatol; 2016 Jun; 74(6):1264-5. PubMed ID: 27185433 [No Abstract] [Full Text] [Related]
8. Vismodegib and surgery combined - effective treatment of locally advanced basal cell carcinoma. Paulsen JF; Øregaard JS; Nielsen AL; Gehl J; Venzo A Acta Oncol; 2016 Dec; 55(12):1492-1494. PubMed ID: 27448604 [No Abstract] [Full Text] [Related]
9. Vismodegib in advanced basal-cell carcinoma. Babacan T; Sarici F; Altundag K N Engl J Med; 2012 Sep; 367(10):969-70; author reply 970. PubMed ID: 22931270 [No Abstract] [Full Text] [Related]
10. Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma. Dessinioti C; Plaka M; Dimitrakopoulou A; Stratigos AJ J Eur Acad Dermatol Venereol; 2019 May; 33(5):e187-e188. PubMed ID: 30653740 [No Abstract] [Full Text] [Related]
11. Vismodegib in advanced basal-cell carcinoma. Henkin RI N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271 [No Abstract] [Full Text] [Related]
12. Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment. Nayyar PM; Chang ALS; Sarin K; Ratner D Dermatol Surg; 2019 Apr; 45(4):608-610. PubMed ID: 30045109 [No Abstract] [Full Text] [Related]
13. Indications and limitations of vismodegib for basal cell carcinoma. Yin VT; Sniegowski M; Esmaeli B JAMA Ophthalmol; 2014 Jul; 132(7):905-6. PubMed ID: 25010179 [No Abstract] [Full Text] [Related]
14. Indications and limitations of vismodegib for basal cell carcinoma--reply. Gill HS; Moscato EE; Silkiss RZ JAMA Ophthalmol; 2014 Jul; 132(7):906. PubMed ID: 25010181 [No Abstract] [Full Text] [Related]
19. Vismodegib resistance in basal cell carcinoma: not a smooth fit. Ridky TW; Cotsarelis G Cancer Cell; 2015 Mar; 27(3):315-6. PubMed ID: 25759014 [TBL] [Abstract][Full Text] [Related]
20. [Vismodegib in metastasized basal cell carcinoma]. Reinders MG; Dirix L; Mosterd K; van Doorn R Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]